Sleep Disorders: Market Analysis 2008-2018

March 19, 2009 - PRLog -- Report Details
More than 80 sleep disorders have been identified. They affect over 200 million people worldwide. The report focuses on the market for following sleep disorders:

• Insomnia
• Restless legs syndrome (RLS)
• Narcolepsy and
• Obstructive Sleep Apnoea / Hypopnea Syndrome (OSAHS)  

The market penetration for insomnia drugs has not reached saturation point. Opportunities remain. But with the introduction of several new products the market is set to see changes, but expansion. This expansion is based on increased general awareness physicians better comprehension of the significance of this disease and the positive role that a sleep medication prescription plays.

At present time there are several prescription sleeping medications available to treat insomnia. The market-focus has been driven by the production of sleep medications with less side-effects and danger of overdose. Prescription benzodiazepines and newer non-benzodiazepine hypnotics developed in the 1990s, such as Imovane, Ambien and Sonata will continue to be the most prescribed. Benzodiazepines are widely used to treat an underlying neurological disorder which is often the underlying cause of insomnia, e.g. anxiety and depression.

Visiongain predicts that market share by volume for insomnia in the US will change significantly from 2008 to 2018. Ambien IR lost its patent protection in April 2007, which opened to generic competition for Zolpidem. Ambien will remain the market leader for the short term, but what will over take it? A generic version of Ambien is expected to achieve strong market share by volume as there is a great demand for zolpidem tartrate for insomnia.

The market share for insomnia treatment will gradually rise after 2012, which will be due to:

• Market expansion of existing expensive medications into Europe and Japan in particular  
• Market penetration of new medications currently in pipeline.

Other drugs dealt with in this report include:

• Modafinil (Provigil) is the first in a new class of wake-promoting drugs and is currently approved in more than 20 countries for the treatment of excessive daytime sleepiness associated with narcolepsy.
• Provigil is quickly replacing Ritalin, and other CNS stimulants, as the medication of choice for treating daytime sleepiness in narcolepsy. The FDA granted modafinil (Provigil) orphan drug status in 1993.
• Modafinil was initially launched in the US in 1999 for the treatment of narcolepsy. In 2004, modafinil became FDA-approved prescription medicine for the treatment of excessive sleepiness associated with Obstructive Sleep Apnoea/Hypopnea Syndrome (OSAHS) and Shift Workers Sleep Disorder (SWSD).
• Requip (ropinirole) became the first and only FDA-approved drug treatment for moderate to severe primary Restless Legs Syndrome (RLS) in 2005.


Key findings that will broaden the scope of the sleep disorders market:

• Over the next decade, the development and improvement of sleep disorders therapies will primarily depend on the success of burgeoning technology and innovative approaches.
• It is possible to purchase prescription medications online without producing a prescription. Purchase of online sleep medications has increased and will continue to evolve over the next years.
• The impact of DTC advertising has created an improved awareness of available insomnia treatment.
• This is likely to increase as DTC advertising continues to prosper and the culture becomes more accepting towards insomnia treatment. Visiongain expects the market for sleep disorders to increase, driven by a growing awareness of sleep disorders and by campaigns to promote sleep medications, both by DTC advertising and consumer education. The relaxation of DTC marketing restrictions in the 1990s in the US set the stage for a flow for both branded and unbranded advertising and promotional programmes. Those regulations are prompting more responsible DTC advertising on the industry's part.
• The FDA has requested that all manufacturers of sedative-hypnotic drug products, a class of drugs used to induce and/or maintain sleep, strengthen their product labelling to include stronger warnings concerning potential risks.
• The Committee for Medicinal Products in Human Use (CHMP) of the European Medicines Agency (EMEA) approved Neurim's Circadin a prolonged-release melatonin as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients aged 55 or over. Neurim is actively seeking strategic alliances for the major European markets.

What questions does the report answer?

• Which current or future therapies will drive the sleep disorders market from 2008 to 2018?
• The key companies involved in the market and their analysis?
• What is the patient identification rate for each of the therapeutic areas?
• What is the present state of the disease awareness?
• What R&D opportunities exist for ‘new comers’?

Why should you buy this report?

• This report focuses on the marketed medications and the pipeline development for sleep disorders from 2008 to 2018.  It also discusses the strength and weakness of products, along with the opportunities and threats facing the market.
• The report describes world market situation for sleep disorders, namely insomnia, narcolepsy, RLS and OSAHS, with forecasts made for all key products. It also describes the insomnia market situation in the seven major world markets for sleep medications: the US, Japan, France, Germany, Italy, Spain and the UK, with forecasts for key products.
• The report provides transcripts of visiongain’s interviews with experts in the field of sleep disorders, which reviews the future direction of the sleep disorders treatment market.

Companies Listed
Abbott
Actelion
Alliance
American Insomnia Association
Andx
Apotex
Arena
Astellas
Avant
Aventis
Bayer
Boehringer Ingelheim
Caraco
Carlsbad
Cephalon
Dr. Reddy's
Elan
Eli Lilly
Drug Enforcement Administration (DEA)
European Patent Office
FDA
Genpharm
GlaxoSmithKline
Hoffman-Roche
Hypnion
Ipsen
Johnson & Johnson
King
Lek
Lundbeck
Mallinckrodt
Merck
Mutual
MHRA
Mylan
National Sleep Foundation
NCSDR
Neurim
Neurocrine
Neurogen
NHLBI
NICE
NIH
NovaDel
Novartis
Orphan
Pfizer
Pharmaceutical Researchers and Manufacturers of America (PhRMA)
Questcor
Ranbaxy
Roche
Rhone-Poulenc Rorer
Roxane
Royal Pharmaceutical Society of Great Britain (RPSGB)
Sanofi-Aventis
Schering-Plough
Sepracor
Shionogi
Shire
Skye
Synthon
Takeda
Teva
Tikvah
UCB
Valeant
Vanda
Watson
Wyeth
XenoPort

Visiongain ltd.
4th Floor,
BSG House,
226 236 City Road,
London
EC1V 2QY
United Kingdom

Telephone: +44 (0) 20 7336 6100
Fax: +44 (0) 20 7549 9930
info@visiongainglobal.com
Or Visit at: http://www.visiongain.com/Report.aspx?rid=274
Or http://www.visiongain.com

# # #

Visiongain is an independent business information provider for the Telecoms, Pharmaceutical and Defence industries. We organise conferences, publish reports and newsletters, and provide consultancy services.